Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients

Standard

Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients. / Karagiannis, Panagiotis; Correa, Isabel; Chauhan, Jitesh; Cheung, Anthony; Dominguez-Rodriguez, Diana; Terranova Barberio, Manuela; Harris, Robert J; Crescioli, Silvia; Spicer, James; Bokemeyer, Carsten; Lacy, Katie E; Karagiannis, Sophia N.

In: CLIN EXP IMMUNOL, Vol. 207, No. 1, 28.01.2022, p. 84-94.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Karagiannis, P, Correa, I, Chauhan, J, Cheung, A, Dominguez-Rodriguez, D, Terranova Barberio, M, Harris, RJ, Crescioli, S, Spicer, J, Bokemeyer, C, Lacy, KE & Karagiannis, SN 2022, 'Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients', CLIN EXP IMMUNOL, vol. 207, no. 1, pp. 84-94. https://doi.org/10.1093/cei/uxab005

APA

Karagiannis, P., Correa, I., Chauhan, J., Cheung, A., Dominguez-Rodriguez, D., Terranova Barberio, M., Harris, R. J., Crescioli, S., Spicer, J., Bokemeyer, C., Lacy, K. E., & Karagiannis, S. N. (2022). Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients. CLIN EXP IMMUNOL, 207(1), 84-94. https://doi.org/10.1093/cei/uxab005

Vancouver

Karagiannis P, Correa I, Chauhan J, Cheung A, Dominguez-Rodriguez D, Terranova Barberio M et al. Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients. CLIN EXP IMMUNOL. 2022 Jan 28;207(1):84-94. https://doi.org/10.1093/cei/uxab005

Bibtex

@article{88999c74255e4acd81aca05413cf91c3,
title = "Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients",
abstract = "Human B cells and their expressed antibodies are crucial in conferring immune protection. Identifying pathogen-specific antibodies following infection is possible due to enhanced humoral immunity against well-described molecules on the pathogen surface. However, screening for cancer-reactive antibodies remains challenging since target antigens are often not identified a priori and the frequency of circulating B cells recognizing cancer cells is likely very low. We investigated whether combined ex vivo culture of human B cells with three innate stimuli, interleukin-17 (IL-17), B-cell activation factor (BAFF), and the toll-like receptor 9 (TLR-9) agonist DNA motif CpG ODN 2006 (CpG), each known to activate B cells through different signalling pathways, promote cell activation, proliferation, and antibody production. Combined IL-17+BAFF+CpG prolonged B-cell survival and increased proliferation compared with single stimuli. IL-17+BAFF+CpG triggered higher IgG secretion, likely by activating differentiated, memory and class-switched CD19+CD20+CD27+IgD- B cells. Regardless of anti-FOLR antibody seropositive status, IL-17+BAFF+CpG combined with a monovalent tumour-associated antigen (folate receptor alpha [FOLR]) led to secreted antibodies recognizing the antigen and the antigen-expressing IGROV1 cancer cells. In a seropositive individual, FOLR stimulation favoured class-switched memory B-cell precursors (CD27-CD38-IgD-), class-switched memory B cells and anti-FOLR antibody production, while IL-17+BAFF+CpG combined with FOLR, promoted class-switched memory B-cell precursors and antibody-secreting (CD138+IgD-) plasma cells. Furthermore, IL-17+BAFF+CpG stimulation of peripheral blood B cells from patients with melanoma revealed tumour cell-reactive antibodies in culture supernatants. These findings suggest that innate signals stimulate B-cell survival and antibody production and may help identify low-frequency antigen-reactive humoral responses.",
author = "Panagiotis Karagiannis and Isabel Correa and Jitesh Chauhan and Anthony Cheung and Diana Dominguez-Rodriguez and {Terranova Barberio}, Manuela and Harris, {Robert J} and Silvia Crescioli and James Spicer and Carsten Bokemeyer and Lacy, {Katie E} and Karagiannis, {Sophia N}",
note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Immunology.",
year = "2022",
month = jan,
day = "28",
doi = "10.1093/cei/uxab005",
language = "English",
volume = "207",
pages = "84--94",
journal = "CLIN EXP IMMUNOL",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients

AU - Karagiannis, Panagiotis

AU - Correa, Isabel

AU - Chauhan, Jitesh

AU - Cheung, Anthony

AU - Dominguez-Rodriguez, Diana

AU - Terranova Barberio, Manuela

AU - Harris, Robert J

AU - Crescioli, Silvia

AU - Spicer, James

AU - Bokemeyer, Carsten

AU - Lacy, Katie E

AU - Karagiannis, Sophia N

N1 - © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Immunology.

PY - 2022/1/28

Y1 - 2022/1/28

N2 - Human B cells and their expressed antibodies are crucial in conferring immune protection. Identifying pathogen-specific antibodies following infection is possible due to enhanced humoral immunity against well-described molecules on the pathogen surface. However, screening for cancer-reactive antibodies remains challenging since target antigens are often not identified a priori and the frequency of circulating B cells recognizing cancer cells is likely very low. We investigated whether combined ex vivo culture of human B cells with three innate stimuli, interleukin-17 (IL-17), B-cell activation factor (BAFF), and the toll-like receptor 9 (TLR-9) agonist DNA motif CpG ODN 2006 (CpG), each known to activate B cells through different signalling pathways, promote cell activation, proliferation, and antibody production. Combined IL-17+BAFF+CpG prolonged B-cell survival and increased proliferation compared with single stimuli. IL-17+BAFF+CpG triggered higher IgG secretion, likely by activating differentiated, memory and class-switched CD19+CD20+CD27+IgD- B cells. Regardless of anti-FOLR antibody seropositive status, IL-17+BAFF+CpG combined with a monovalent tumour-associated antigen (folate receptor alpha [FOLR]) led to secreted antibodies recognizing the antigen and the antigen-expressing IGROV1 cancer cells. In a seropositive individual, FOLR stimulation favoured class-switched memory B-cell precursors (CD27-CD38-IgD-), class-switched memory B cells and anti-FOLR antibody production, while IL-17+BAFF+CpG combined with FOLR, promoted class-switched memory B-cell precursors and antibody-secreting (CD138+IgD-) plasma cells. Furthermore, IL-17+BAFF+CpG stimulation of peripheral blood B cells from patients with melanoma revealed tumour cell-reactive antibodies in culture supernatants. These findings suggest that innate signals stimulate B-cell survival and antibody production and may help identify low-frequency antigen-reactive humoral responses.

AB - Human B cells and their expressed antibodies are crucial in conferring immune protection. Identifying pathogen-specific antibodies following infection is possible due to enhanced humoral immunity against well-described molecules on the pathogen surface. However, screening for cancer-reactive antibodies remains challenging since target antigens are often not identified a priori and the frequency of circulating B cells recognizing cancer cells is likely very low. We investigated whether combined ex vivo culture of human B cells with three innate stimuli, interleukin-17 (IL-17), B-cell activation factor (BAFF), and the toll-like receptor 9 (TLR-9) agonist DNA motif CpG ODN 2006 (CpG), each known to activate B cells through different signalling pathways, promote cell activation, proliferation, and antibody production. Combined IL-17+BAFF+CpG prolonged B-cell survival and increased proliferation compared with single stimuli. IL-17+BAFF+CpG triggered higher IgG secretion, likely by activating differentiated, memory and class-switched CD19+CD20+CD27+IgD- B cells. Regardless of anti-FOLR antibody seropositive status, IL-17+BAFF+CpG combined with a monovalent tumour-associated antigen (folate receptor alpha [FOLR]) led to secreted antibodies recognizing the antigen and the antigen-expressing IGROV1 cancer cells. In a seropositive individual, FOLR stimulation favoured class-switched memory B-cell precursors (CD27-CD38-IgD-), class-switched memory B cells and anti-FOLR antibody production, while IL-17+BAFF+CpG combined with FOLR, promoted class-switched memory B-cell precursors and antibody-secreting (CD138+IgD-) plasma cells. Furthermore, IL-17+BAFF+CpG stimulation of peripheral blood B cells from patients with melanoma revealed tumour cell-reactive antibodies in culture supernatants. These findings suggest that innate signals stimulate B-cell survival and antibody production and may help identify low-frequency antigen-reactive humoral responses.

U2 - 10.1093/cei/uxab005

DO - 10.1093/cei/uxab005

M3 - SCORING: Journal article

C2 - 35020866

VL - 207

SP - 84

EP - 94

JO - CLIN EXP IMMUNOL

JF - CLIN EXP IMMUNOL

SN - 0009-9104

IS - 1

ER -